Tobira Therapeutics Completes $13M Convertible Note Financing

tobiraTobira Therapeutics, Inc., a South San Francisco, CA-based clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, completed a $13m convertible note financing.

Backers included Abingworth LLP, Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. and Stonepine Capital Management LLC, and current investors. The closing of the note financing and the investment by Tobira’s current investors was contemplated by the previously announced merger agreement with Regado Biosciences (NASDAQ: RGDO), which is expected to close in the second quarter of 2015.

The company intends to use the funds for the clinical program with cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor targeting immuno-inflammation and fibrogenesis in non-alcoholic steatohepatitis (NASH), a disease associated with obesity and diabetes that often leads to liver cirrhosis.

Tobira is led by Laurent Fischer, M.D., chairman and CEO.

FinSMEs

09/03/2015

Join the discussion